Impact of COVID-19 and Other Infectious Diseases on Sales and Business Activities
First written in FY2023. 1 of 3 entries say "Mitigated", first in FY2024-Q1. Latest entry: FY2025.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
38 other companies' latest entry also says "Dropped".
- FY2025DroppedAnnual reportThis filing does not include the impact of COVID-19 or other infectious diseases on sales and business activities among the business risks.
- FY2024-Q1MitigatedAnnual report
「During the first-quarter cumulative period, the Japanese economy remained uncertain. Although the impact of COVID-19 eased and an economic recovery was anticipated, inflation and growing upward pressure on interest rates continued against a backdrop of developments in the Middle East and the prolonged situation in Ukraine, high global resource and energy prices and economic conditions characterized by yen depreciation.」
States that the impact of COVID-19 had eased, indicating a lessening of the previously disclosed infectious-disease risk. - FY2023First statedAnnual report
「If requests for prolonged self-restraint continue, this could affect results through delays in new sales and cancellations caused by deteriorating performance among existing KAIKURA users.」
Countermeasures include business processes suited to working from home and systems for preventing infection and its spread.